- Imidazo[1,2-a]pyrazines as novel PI3K inhibitors
-
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.
- Martínez González, Sonia,Hernández, Ana Isabel,Varela, Carmen,Rodríguez-Arístegui, Sonsoles,Alvarez, Rosa María,García, Ana Belén,Lorenzo, Milagros,Rivero, Virginia,Oyarzabal, Julen,Rabal, Obdulia,Bischoff, James R.,Albarrán, Maribel,Cebriá, Antonio,Alfonso, Patricia,Link, Wolfgang,Fominaya, Jesús,Pastor, Joaquín
-
-
Read Online
- DUAL KINASE-BROMODOMAIN INHIBITORS
-
Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.
- -
-
Page/Page column 95; 140
(2021/12/12)
-
- Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing
-
The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
- -
-
Page/Page column 49; 241; 242
(2018/06/26)
-
- A 2 - amino pyrazine derivatives of preparation method
-
The invention discloses a 2 - amino pyrazine derivatives of preparation method, comprises the following steps: C1: to 2 - cyano pyrazine is sequentially added in the sodium hypochlorite solution and alkali, then stirring, to obtain 2 - amino pyrazine; C2: step C1 of the obtained 2 - amino pyrazine join the brominating agent performing the bromination reaction, to obtain 2 - amino - 3, 5 - two bromine pyrrole qin; C3: step C2 of the obtained 2 - amino - 3, 5 - two bromine pyrrole qin with morpholine substitution reaction to obtain 2 - amino - 5 - bromo - 3 - morpholinyl pyrazine solution; C4: the 2 - amino - 5 - bromo - 3 - morpholinyl [...] is distilled out of the organic solvent, then wash the static separation, to obtain 2 - amino - 5 - bromo - 3 - morpholinyl pyrazine crude product. In order to 2 - cyano pyrazine as raw materials, is easy to prepare or procurement, after acid-base reaction, bromination reaction, the substitution reaction, distillation filtering and the like four-step operation preparation, preparation method is simple and convenient operation, the final preparation of the obtained 2 - amino pyrazine derivatives have high yield, is suitable for industrial production.
- -
-
Paragraph 0012; 0013; 0014
(2018/10/19)
-
- Synthesis and biological evaluation of novel 8-morpholinoimidazo[1,2-a]pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides
-
Herein we designed and synthesized three series of novel 8-morpholinoimidazo[1,2-a] pyrazine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides (compounds 12a-g, 13a-g and 14a-g). All the compounds were evaluated for their IC50 values against three cancer cell lines (A549, PC-3 and MCF-7). Most of the target compounds exhibited moderate cytotoxicity against the three cancer cell lines. Two selected compounds 14b, 14c were further tested for their activity against PI3Kα kinase, and the results indicated that compound 14c showed inhibitory activity against PI3Kα kinase with an IC50 value of 1.25 μM. Structure-activity relationships (SARs) and pharmacological results indicated that the replacement of the thiopyranopyrimidine with an imidazopyrazine was beneficial for the activity and the position of aryl group has a significant influence to the activity of these compounds. The compounds 13a-g in which an aryl group substituted at the C-4 position of the pyridine ring were more active than 12a-g substituted at the C-5 position. Moreover, the cytotoxicity of compounds 14a-g bearing phenylpyrimidine-carboxamides was better than that of the compounds 12a-g, 13a-g bearing phenylpyridine-carboxamides. Furthermore, the substituents on the benzene ring also had a significant impact on the cytotoxicity and the pharmacological results showed that electron donating groups were beneficial to the cytotoxicity.
- Xu, Shan,Sun, Chengyu,Chen, Chen,Zheng, Pengwu,Zhou, Yong,Zhou, Hongying,Zhu, Wufu
-
-
- Heterocyclic-pyrimindine or pyrazine compound containing biarylamide structure and application thereof
-
The invention discloses a heterocyclic-pyrimindine or pyrazine compound containing a biarylamide structure. The heterocyclic-pyrimindine or pyrazine compound is as shown in a general formula I or II, wherein the general formula I and the general formula II are shown in the description. The heterocyclic-pyrimindine or pyrazine compound containing the biarylamide structure, and pharmaceutically acceptable salts, hydrates or solvates thereof are used as active components, and are mixed with a pharmaceutically acceptable carrier or excipient to prepare a composition; and the composition is prepared into clinically acceptable preparations. The compound provided by the invention can be used for treating and/or preventing proliferative diseases, and treating and/or preventing prostate cancer, lung cancer and cervical cancer.
- -
-
Paragraph 0137; 0138; 0139
(2017/07/22)
-
- Identification of novel PI3K inhibitors through a scaffold hopping strategy
-
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery of novel PI3K inhibitors. Compounds were designed based on the chemical structure of the lead compound ETP-46321, a potent PI3
- Martínez González, Sonia,Hernández, Ana Isabel,álvarez, Rosa María,Rodríguez, Antonio,Ramos-Lima, Francisco,Bischoff, James R.,Albarrán, María Isabel,Cebriá, Antonio,Hernández-Encinas, Elena,García-Arocha, Jennifer,Cebrián, David,Blanco-Aparicio, Carmen,Pastor, Joaquín
-
p. 4794 - 4799
(2017/10/12)
-
- A 2-amino-pyrazine derivatives method for the preparation of (by machine translation)
-
The invention relates to a 2-amino-pyrazine derivatives preparation method, which belongs to the technical field of organic synthesis. Using 2-cyano pyrazine as the raw material, by adding sodium hypochlorite solution and alkali, to obtain 2-amino-pyrazine, then bromination reaction to obtain 2-amino -3,5- [...], then to 2-amino -3,5- [...] as raw materials are respectively and morpholine, piperazine and pyrrolizinone the substitution reaction, respectively obtained 2-amino-5-bromo-3-morpholinyl-pyrazine, 2-amino-5-bromo-3-Piperazinylpyrazine and 2-amino-5-bromo-3-pyrrolidinyl pyrazine. This invention utilizes the 2-cyano pyrazine as the raw material, to preparation of different types of 2-amino-pyrazine derivatives, cheap and easily obtained raw materials, the operation is simple, high yield of target product. (by machine translation)
- -
-
Paragraph 0026; 0027; 0028
(2016/10/08)
-
- New use of bis(benzotriazolyl)-1,2-(dialkylamino)ethanes for the synthesis of 2-H-3-dialkylamino imidazo[1,2-a]pyrazine derivatives
-
First direct synthesis of 2-H-3-N-dialkyl-imidazo[1,2-a]pyrazines is described. This approach makes use of accessible substituted pyrazines and the assistance of benzotriazole. In such a manner we accomplished the introduction of cyclic amines at C-3 of the scaffold in a convenient formal cyclisation procedure. Detailed examples and utility of this approach are presented herein.
- Pastor, Joaquín,Rodríguez-Arístegui, Sonsoles,Hernández, Ana Isabel,Varela, Carmen,Salgado, Antonio,Martínez, Sonia
-
scheme or table
p. 1082 - 1084
(2012/03/26)
-
- IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS
-
There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
- -
-
Page/Page column 91
(2012/04/11)
-
- FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS
-
There is provided compounds of formula (I), wherein A1, A2, A3, A4, n, the dotted lines, B1, B1a, B2, B2a, B3, B3a, B4, B4a, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
- -
-
Page/Page column 77
(2011/04/24)
-
- INHIBITORS OF PI3 KINASE
-
There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
- -
-
Page/Page column 117
(2011/08/08)
-
